Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria

Faculty	Medicine	Year:	2020
Type of Publication:	ZU Hosted	Pages:
Authors:
Journal:	Breast Care Karger	Volume:

Keywords :	Adjuvant Chemotherapy , Patients with Breast Cancer
Abstract:	-Oncotype DX assay recurrence score (ODX-RS) cut-off values have recently changed after the publication of the TAILOR-X trial results. We aim to explore decisions for adjuvant chemotherapy (ACT) based on physicians’ clinical assessment and the evolving ODX-RS. -Overtreatment and discrepancies in the management of patients with ER+/Her2–/LN– early BC can be minimized by the implementation of ODX genomic assay. Some differences in ACT recommendations exist between ODX-RS-1 and ODX-RS-2.

Author Related Publications

Heba Fekry Abdel Majid Taha, "SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell carcinoma (cc-RCC): Clinicopathological and prognostic significance", Elsevier,science direct, 2018 More
Shereen Mostafa Saleh Elshorbagy, "prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study", PMID: 35506035, 2022 More
Rasha Mohamed Mostafa Hagag, "Prognostic Value of Snail-1and Beta-Catenin Immunostaining in Astrocytoma.", International Journal of Advanced Research (2016), Volume 4, Issue 4, 1055-1066, 2016 More
Rasha Mohamed Mostafa Hagag, "Immunohistochemical expressions of SQSTM1/p62, Beclin-1, and SOX4 in infiltrating duct carcinoma of the breast", Egyptian Journal of Pathology, 2016 More